Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Boxes of the injectable weight-loss drug Wegovy are seen in a pharmacy in Chicago on April ... The efforts by Eli Lilly and ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

That compares with up to 16% from Novo Nordisk’s Wegovy, and up to 22.5% from Eli Lilly’s rival Mounjaro when administered alongside lifestyle interventions such as improved diet, exercise and sleep.

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...

Lilly and Novo Nordisk are hoping to win over employers on the idea that obesity and its complications are already a huge cost in terms of healthcare, workers' compensation and disability. By offering ...

There’s no hard-and-fast rule for how long it’s safe to stay on Ozempic for weight loss. Novo Nordisk-sponsored studies lasting up to two years show that semaglutide is safe.